JPMorgan starts Savara at Overweight, betting on November FDA decision
JPMorgan initiated coverage of Savara with an Overweight rating and a $12 target, implying 146% upside from the $4.88 close. The stock has fallen 30% since December after the FDA delayed its decision on Molbreevi to Nov. 22 and expected losses widened. The call depends heavily on the upcoming FDA decision, with analysts projecting a launch and rapid sales growth if approved.
JPMorgan began covering Savara with an Overweight rating and a $12 target, which was 146% above the $4.88 close. The shares had fallen 30% from their December peak. The FDA postponed its ruling on Molbreevi, Savara’s sole candidate, to Nov. 22 after treating company responses as a major amendment; Savara said no safety, efficacy, or manufacturing issues were cited.
Second-quarter loss was $0.16 per share, a cent wider than consensus, and projected losses for 2026 and 2027 have increased. All nine tracked analysts rate the stock Buy or Outperform, with an $11 average target and a $9–$16 range. Sales estimates start near zero and rise to $82 million in 2027 and $206 million in 2028.
The FDA’s Nov. 22 decision could affect patients who may gain or lose access to a new treatment option, along with Savara’s employees, partners, and shareholders. An approval may support hiring, launch spending, and broader confidence in single-asset biotech firms; a rejection or further delay could weaken the company and chill investment in similar developers. For clinicians and payers, the drug’s pricing and uptake may shape treatment discussions and budget planning, though the ultimate societal effect remains uncertain until regulators rule.